Digest
Network
How does it work
Network
/
Society
Ul
Not verified
Ultragenyx Pharmaceutical Inc.
favorite
Follow updates
What we write about
Medical Health Wellness
Want ads
2
Press releases
View all press releases
arrow_forward
Spread
check
Save time in your work
check
Increases chances of spread
check
Get to know the most accredited journalists
add
Create your statement
Finds
check
Customize your digest
check
Save and organize press releases
check
30,000 Companies and Press Officers
add
Open your profile
calendar_today
08/10/2025
upload
Medical Health Wellness
Want ads
Ultragenyx annuncia l'approvazione da parte dell'AIFA (Agenzia Italiana del Farmaco) del rimborso di Evkeeza® (evinacumab) per i pazienti pediatrici di età pari a 6 mesi con ipercolesterolemia familiare omozigote (HoFH)
Source
Ultragenyx Pharmaceutical Inc.
Issuer
GLOBENEWSWIRE
target
1.00
bookmark_border
0
calendar_today
05/01/2025
upload
Medical Health Wellness
European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
Source
Ultragenyx Pharmaceutical Inc.
Issuer
GLOBENEWSWIRE
target
1.00
bookmark_border
0
ios_share
Share company
Contact details
Social Media
favorite
Followers
0
target
Compatibility
0
add to favourites
